Media coverage about Oramed Pharmaceuticals (NASDAQ:ORMP) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.8283207810166 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern’s scoring:

Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) opened at $7.64 on Tuesday. The firm has a market capitalization of $110.94, a PE ratio of -9.92 and a beta of 0.22. Oramed Pharmaceuticals has a fifty-two week low of $5.85 and a fifty-two week high of $11.34.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings data on Thursday, January 11th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.06. The firm had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.62 million. Oramed Pharmaceuticals had a negative return on equity of 49.94% and a negative net margin of 169.17%. sell-side analysts anticipate that Oramed Pharmaceuticals will post -1.19 EPS for the current fiscal year.

ORMP has been the topic of a number of analyst reports. ValuEngine raised Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a research report on Wednesday, November 22nd. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 target price on shares of Oramed Pharmaceuticals in a research report on Tuesday, January 16th.

TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://theolympiareport.com/2018/02/13/oramed-pharmaceuticals-ormp-receiving-somewhat-favorable-press-coverage-analysis-shows.html.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Insider Buying and Selling by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.